Fidelity Investments
INMB icon

Fidelity Investments’s INmune Bio INMB Stock Holding History

Fidelity Investments’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$54.9K Buy
33,689
+20,099
+148% +$27.8K ﹤0.01% 4273
2026
Q1 		$15.4K Sell
13,590
-507
-4% -$722 ﹤0.01% 4617
2025
Q4 		$22K Buy
14,097
+10,926
+345% +$19.5K ﹤0.01% 4422
2025
Q3 		$6.56K Buy
3,171
+661
+26% +$1.51K ﹤0.01% 4714
2025
Q2 		$5.8K Sell
2,510
-463
-16% -$3.4K ﹤0.01% 4678
2025
Q1 		$23.2K Buy
2,973
+1,344
+83% +$10.7K ﹤0.01% 4170
2024
Q4 		$7.61K Buy
1,629
+205
+14% +$1.07K ﹤0.01% 4548
2024
Q3 		$7.67K Buy
1,424
+1,339
+1,575% +$9.52K ﹤0.01% 4513
2024
Q2 		$750 Sell
85
-500
-85% -$4.93K ﹤0.01% 4827
2024
Q1 		$6.87K Buy
585
+500
+588% +$6.04K ﹤0.01% 4406
2023
Q4 		$957 Hold
85
– – ﹤0.01% 4754
2023
Q3 		$581 Hold
85
– – ﹤0.01% 4699
2023
Q2 		$772 Sell
85
-7
-8% -$56 ﹤0.01% 4752
2023
Q1 		$594 Buy
92
+83
+922% +$668 ﹤0.01% 4779
2022
Q4 		$57 Buy
+9
New +$64 ﹤0.01% 4928

Other funds holding INMB

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Fidelity Investments's INMB Position: Q2 2026 in Review

Fidelity Investments increased its INmune Bio (INMB) stake by 148% in Q2 2026, buying an estimated $27.8K and bringing the position to 33,689 shares worth $54.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4273.

Fidelity Investments first reported a position in INMB in Q4 2022 and has held it in 15 quarters since. 83 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

  • Fidelity Investments held 33,689 shares of INmune Bio worth $54.9K as of Q2 2026.
  • Fidelity Investments bought 20,099 INmune Bio shares in Q2 2026, an estimated $27.8K.
  • INmune Bio made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #4273 holding.
  • Fidelity Investments first reported a position in INmune Bio in Q4 2022 and has held it in 15 quarters since.
  • 83 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.